Views & Analysis Gene editing: beyond the hype Genome editing is an exciting but still nascent field, and companies in the area face as many obstacles as they do opportunities.
Partner Content Partner Content Targeting Solid & Liquid Malignancies with the Same CAR Cell and Gene Therapy
News J&J plots filings after psoriasis drug clears phase 3 test Johnson & Johnson has moved a step closer to filing a potential first-in-class therapy for psoriasis after the drug hit the mark in a phase 3 trial.
Digital Sponsored Decoding physician prescribing behaviour: A data-driven jour... Identifying high-volume prescribers and engaging with key opinion leaders (KOLs) in a target therapeutic area can be a challenge.
